Vanda Pharmaceuticals (VNDA) Capital Expenditures (2011 - 2026)
Vanda Pharmaceuticals (VNDA) reported Capital Expenditures of $221000.0 for Q1 2026, down 49.31% on a YoY basis from $436000.0 in Q1 2025, and up 116.67% sequentially from $102000.0 in Q4 2025.
Vanda Pharmaceuticals (VNDA) Capital Expenditures (2011 - 2026) Analysis & Trends
Vanda Pharmaceuticals (VNDA) has 16 years of Capital Expenditures data on file, last reported at $221000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 49.31% year-over-year to $221000.0; the trailing twelve-month figure through Mar 2026 stood at $783000.0 (down 14.8% YoY), and the FY2025 full-year result was $998000.0, up 103.67% from the prior year.
- Capital Expenditures rose to $221000.0 in Q1 2026, from $102000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $436000.0 in Q1 2025 to a low of $7000.0 in Q1 2024.
- A 5-year average of $163000.0 and a median of $161000.0 in 2024 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures plunged 86.27% in 2024 and soared 6128.57% in 2025, its largest moves.
- Tracing VNDA's Capital Expenditures over 5 years: stood at $263000.0 in 2022, then retreated by 3.8% to $253000.0 in 2023, then fell by 15.42% to $214000.0 in 2024, then sank by 52.34% to $102000.0 in 2025, then soared by 116.67% to $221000.0 in 2026.
- Business Quant data shows VNDA's Capital Expenditures at $221000.0 in Q1 2026, $102000.0 in Q4 2025, and $161000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Vanda Pharmaceuticals | 318.71 Mn | 116.40 Mn | 48.56 Mn | 221,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 221,000.00 |
| Mar 31, 2026 | 221,000.00 |
| Dec 31, 2025 | 102,000.00 |
| Dec 31, 2025 | 102,000.00 |
| Sep 30, 2025 | 161,000.00 |
| Sep 30, 2025 | 161,000.00 |
| Jun 30, 2025 | 299,000.00 |
| Jun 30, 2025 | 299,000.00 |
| Mar 31, 2025 | 436,000.00 |
| Mar 31, 2025 | 436,000.00 |
| Dec 31, 2024 | 214,000.00 |
| Dec 31, 2024 | 214,000.00 |
| Sep 30, 2024 | 161,000.00 |
| Sep 30, 2024 | 161,000.00 |
| Jun 30, 2024 | 108,000.00 |
| Jun 30, 2024 | 108,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Dec 31, 2023 | 253,000.00 |
| Dec 31, 2023 | 253,000.00 |